Takeda Pharmaceutical Acquires Shire Plc for US$ 62 Billion

Takeda Pharmaceutical Company Ltd. in its largest deal ever, announced the acquisition of Shire Plc. at around US$ 62 (£46 billion) on May 8, 2018. Shire’s complementary product portfolio and pipeline in gastroenterology and neuroscience, two of the core business segments of Takeda, may have been the primary focus for this acquisition, as highlighted in Takeda CEO’s, Christophe Weber, statement post the announcement of the acquisition. This acquisition will not only make the combined entity (Takeda + Shire) one of the leading players in gastroenterology and neuroscience markets, but also one of the top 10 pharmaceutical companies on the basis of revenue in 2017. Moreover, Shire has multiple products in pipeline for rare diseases, which will help Takeda to establish itself as a strong contender in this (i.e. rare disease drugs) growing market. The acquisition will also make the combined entity resilient and prepared for a tough environment, especially in the U.S., as stated by Takeda CEO in one of the recent interview. The combined entity is expected to gain about 50% of its revenue from the U.S. The U.S. is witnessing conflicts regarding prices of pharmaceutical drugs and innovative tactics of delaying entry of generics in the market.

Click the link below for complete Analysis of the Acquisition,

https://www.coherentmarketinsights.com/insightsanalysispdf/Final-Takeda-Acquisition-Analysis-Article.pdf

The company is expecting the acquisitions to go according to its plans, however, the value of the deal, which is about 4 times the revenue of Takeda and 2x its market value has made the investor worrisome about the future of Takeda. This is reflected in continuous decline of the Takeda share price since March, when rumors about this acquisition came out in public. However, for now the company (i.e. Takeda) has managed to get receive fund by entering into ‘364-Day Bridge Credit Agreement” with the initial lenders including JP Morgan Chase Bank, N.A., Sumitomo Mitsui Banking Corporation, and MUFG Bank, Ltd. for US$ 30.85 Bn, which is expected to significantly aid the company in the acquisition.

 

You may be interested

Machine Learning-Based Smartphone App to Evaluate Parkinson’s Symptoms
Information Technology and Gadgets
Information Technology and Gadgets

Machine Learning-Based Smartphone App to Evaluate Parkinson’s Symptoms

Mohit Joshi - September 21, 2018

New smartphone app HopkinsPD, utilizes the smartphone's microphone, touchscreen, and accelerometer to examine patients for symptoms while they perform daily tasks Parkinson’s affects central nervous system of…

Depressive Thoughts Affect Working Memory
Healthcare
Healthcare

Depressive Thoughts Affect Working Memory

Mohit Joshi - September 20, 2018

Researchers establish a link between prolonged depression and reduced working memory, according to a new study published in March 2018. Researchers reveal that dysphoria, which is a…

Myeloproliferative Neoplasms Treatment Market – Current Trends and Future Opportunities by 2026
Healthcare
Healthcare

Myeloproliferative Neoplasms Treatment Market – Current Trends and Future Opportunities by 2026

Albert R - September 20, 2018

Coherent Market Insights added Latest Research Report titled “Myeloproliferative Neoplasms Treatment Market Insights by Manufacturers, Growth, Trends, Regions, Product Type and Application, Geography, Forecast to 2026” to…

Most from this category